Friday, September 14, 2018

Hepatitis C; Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 still work for Koreans?

Clin Mol Hepatol. 2018 Sep 11. doi: 10.3350/cmh.2018.1009. [Epub ahead of print]
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Yeon JE

PMID: 30200750 DOI: 10.3350/cmh.2018.1009 

Full-Text

Editorial
According to the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C,1 treatment options for genotype 2 patients are sofosbuvir plus ribavirin (SOF+R), SOF plus daclatasvir, glecaprevir plus pibrentasvir, SOF plus velpatasvir and pegylated interferon alpha plus ribavirin (PEG-IFN+R). Except in cases where only patients who cannot use the direct acting antivirals (DAAs), PEG-IFN+R is replaced by DAAs.
Posted by at
File Under ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)